论文部分内容阅读
同种肾移植术后,长期使用免疫抑制药物,容易发生恶性肿瘤。本文拟就发病概况、肿瘤类型、发病机制、防治和预后等问题作一综述。一、发病概况自1969年以来,人们对于脏器移植术后并发恶性肿瘤有了进一步的认识。据美国肿瘤移植登记处的资料,脏器移植术后并发恶性肿瘤的发病率为5～6％,约大于同龄普通人群的100倍。Starzl等的肾移植病人66例,术后5～10年的恶性肿瘤发生率超过6％。术后存活时间越长,恶性肿瘤发生率越高,计每年递增5％,9年后可达44％。
After the same type of kidney transplantation, long-term use of immunosuppressive drugs, prone to malignant tumors. This article intends to provide an overview of morbidity, tumor type, pathogenesis, prevention and prognosis. First, the incidence profile Since 1969, people have further understanding of malignant tumors after organ transplantation. According to the American Cancer Transplant Registry, the incidence of malignant tumors after organ transplantation is 5-6%, which is about 100 times greater than that of the general population at the same age. Starzl and other kidney transplant patients in 66 cases, 5 to 10 years after the incidence of malignant tumors more than 6%. The longer the survival time after surgery, the higher the incidence of malignant tumors, which increases by 5% every year, and reaches 44% after 9 years.